Shots:

• The US FDA has placed a clinical hold on the P-I/II clinical trial of SEL-302 in patients with MMA
• On Nov 23, the US FDA notified the company of the clinical hold via a letter & recommends the updates of additional information on the chemistry, manufacturing, and controls related to the MMA-101 product
• The company plans to work closely with the US FDA to address the requests for additional information and will provide an additional update in 2022

Ref: Selecta Bioscience | Image: Selecta BIoscience